Agent and method for inhibiting skin damage caused by nonenal
Nonenal masking agents like benzaldehyde and others block nonenal's binding to olfactory receptors, addressing skin thinning and cell proliferation inhibition, thereby preventing and improving skin aging effects.
Patent Information
- Application Number
- JP2021551463
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-04
- Filing Date
- 2020-10-01
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2040-10-01
AI Technical Summary
The adverse effects of nonenal on skin, particularly skin thinning and inhibition of cell proliferation, have not been fully elucidated, and there is a need to suppress these effects.
The use of nonenal masking agents such as benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde to inhibit skin damage by reducing or blocking the binding of nonenal to cyclic nucleotide-gated ion channels in olfactory receptors, thereby suppressing the electrical signals associated with skin thinning and cell proliferation inhibition.
These agents effectively prevent and improve skin thinning, wrinkles, sagging, and skin aging by inhibiting nonenal-induced skin damage, enhancing skin elasticity and function.
Smart Images

Figure 0007588084000011 
Figure 0007588084000012 
Figure 0007588084000013
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent and a method for inhibiting skin damage caused by nonenal. [Background technology]
[0002] Unsaturated aldehydes such as nonenal are known to cause aging odor, and various substances have been developed to mask this odor (Patent Documents 1 and 2). Carbonylation inducers such as nonenal are also known to cause skin yellowing (Patent Document 3).
[0003] On the other hand, it is also known that a pleasant scent can reduce stress and indirectly improve skin condition. For example, it has been reported that fragrance products containing rose oil and the like have the effect of secreting oxytocin, which promotes IGF-1 production in dermal and epidermal cells (Patent Document 4).
[0004] However, it has not been fully elucidated so far how malodorous substances such as nonenal affect the skin, and if they do, how to suppress such effects. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] Japanese Patent Application Publication No. 11-286423 [Patent Document 2] Japanese Patent Application Publication No. 11-286428 [Patent Document 3] JP 2012-32287 A [Patent Document 4] JP 2011-98898 A [Non-patent literature]
[0006] [Non-Patent Document 1] Takeuchi et. al., The Journal of General Physiology. Vol. 133 No. 6, pp583-601 Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to provide an agent for suppressing skin damage caused by nonenal. [Means for solving the problem]
[0008] The present inventors have discovered that nonenal inhibits the proliferation of skin cells and causes skin damage such as skin thinning. Based on this discovery, they have conducted extensive research into a wide variety of materials and found that nonenal masking agents, including benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde, exhibit skin damage inhibition effects, leading to the present invention.
[0009] This application encompasses the following inventions: (1) A nonenal masking agent for suppressing skin damage caused by nonenal. (2) A skin damage inhibitor comprising a nonenal masking agent. (3) The agent according to (1) or (2), wherein the nonanal masking agent is one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde. (4) The drug described in any one of (1) to (3), wherein the skin damage is skin thinning. (5) A composition comprising the agent according to any one of (1) to (4). (6) A cosmetic method for suppressing skin damage caused by nonenal by administering a nonenal masking agent. (7) The cosmetic method according to (6), wherein the nonanal masking agent is one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde. (8) The cosmetic method according to (6) or (7), wherein the skin damage is skin thinning. (9) A method for suppressing skin damage caused by nonenal in a subject in need of suppressing skin damage caused by nonenal, by administering one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde. (10) The method according to (9), wherein the skin damage is skin thinning. (11) One or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde for treating skin damage caused by nonenal. (12) The compound according to (11), wherein the skin damage is skin thinning. (13) Use of one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde in the manufacture of a medicament for inhibiting skin damage caused by nonenal. Effect of the Invention
[0010] According to the present invention, an agent and method effective for treating skin damage caused by nonenal are provided. Suppression of skin damage caused by nonenal is effective in suppressing skin aging. [Brief description of the drawings]
[0011] [Figure 1]Figure 1 shows the results of Experiment 1-2, and shows the cell viability (%) when various malodorous substances were added, expressed as a relative value with the control result set at 100.0 (two-tailed t-test between control and each malodorous substance, ****P<0.001). [Diagram 2] Figure 2 shows the results of Experiment 2, and shows the cell viability (%) when each concentration of nonenal was added, expressed as a relative value with the control result set at 100.0 (two-tailed t-test for control vs. each concentration of nonenal, ****P<0.001). [Diagram 3] Figure 3 shows the results of Experiment 3-2, and shows the cell viability (%) when various concentrations of each substance to be evaluated were added, expressed as a relative value with the control result set at 100.0 (two-tailed t-test between control and each substance to be evaluated, **P<0.01, ***P<0.001). [Figure 4] Figure 4 shows the results of Experiment 3-3, and shows the cell viability (%) when various evaluation substances and various concentrations of nonenal were added, expressed as a relative value with the control result set at 100.0 (two-tailed t-test for control vs. added nonenal, and added nonenal vs. each evaluation substance, *P<0.05, **P<0.01, ***P<0.001). [Diagram 5] Figure 5 is a set of photographs showing the results when only solvent (ethanol) was added to the 3D skin model created in Experiment 4 (top left: control), when only nonenal was added (bottom left: 50 μM nonenal), or when nonenal and various substances to be evaluated were added (center and right: 50 μM nonenal + 50 μM various substances to be evaluated). [Figure 6] Figure 6 shows the skin thickness when only solvent (ethanol) was added to the 3D skin model created in Experiment 4 (control), when only nonenal was added (nonenal), or when nonenal and various substances to be evaluated were added (nonenal + various substances to be evaluated) as the cross-sectional area of the skin per 1 μm of horizontal skin length (Area μm2 / μm) in the cross-section as shown in the left figure (right figure) (two-tailed t-test for control vs. nonenal added, and nonenal added vs. each substance to be evaluated, **P<0.01, ***P<0.005). [Figure 7]Figure 7 is a set of photographs showing BrdU-positive cells when only solvent (ethanol) was added to the 3D skin model created in Experiment 4 (top left: control), when only nonenal was added (bottom left: 50 μM nonenal), or when nonenal and various substances to be evaluated were added (center and right: 50 μM nonenal + 50 μM various substances to be evaluated). [Figure 8] Figure 8 is a graph showing the number of BrdU-positive cells per mm of horizontal length (cells / mm) in the cross-section of the skin portion shown in Figure 7 when only solvent (ethanol) was added to the 3D skin model created in Experiment 4 (control), when only nonenal was added (nonenal), or when nonenal and various substances to be evaluated were added (nonenal + various substances to be evaluated) (Dunnett's test for control vs. added nonenal, and added nonenal vs. each substance to be evaluated, *P<0.05, **P<0.01). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Nonenal (2-nonenal) is an unsaturated aldehyde having the following structure, and is referred to in this specification as the trans form (t-2-nonenal). [ka]
[0013] Although nonenal has been reported to be related to aging odor and skin yellowing (Patent Documents 1-3), its effect on the skin has not been fully elucidated. However, the present inventors have discovered that nonenal causes skin damage, including skin thinning. Furthermore, the present inventors have found that nonenal masking agents such as benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde exhibit an inhibitory effect on skin damage caused by nonenal. The present invention is based on this discovery.
[0014] A nonenal masking agent is a substance that has a nonenal masking effect, which masks the odor caused by nonenal. The nonenal masking effect refers to covering up the unpleasant odor caused by nonenal.
[0015] In the sense of smell, when an odorant is received by olfactory receptors present in the olfactory cells of the olfactory epithelium, it is converted into an electrical signal by the action of ion channels, and the signal is transmitted from the olfactory nerve to the brain, where it is recognized as an odor. As an ion channel, cyclic nucleotide-gated ion (CNG) channels (hereinafter referred to as CNG channels), which are non-selective ion channels present in the ciliary membrane of olfactory cells, also act, and various odor molecules bind to these channels (Non-Patent Document 1).
[0016] Therefore, in the present invention, the nonenal masking action may be reducing or blocking the binding of nonenal to the CNG channel by binding to nonenal or other means, reducing or blocking the electrical signal generated by binding of nonenal to the olfactory receptor, etc. For example, Non-Patent Document 1 reports that substances such as benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde have a high electrical signal reduction rate (current reduction rate (%)) and masking score for nonenal. Therefore, as the nonenal masking agent of the present invention, although not limited thereto, a substance having a high electrical signal reduction rate or masking score for nonenal measured by the method described in Non-Patent Document 1 can be used. Alternatively, known substances that are known to have a nonenal-masking effect, such as those described in Patent Documents 1 and 2, may be used, and substances with high nonenal-masking effect may be searched for and used by methods such as various sensory tests using odor judges or specific panelists, or methods such as investigating the binding ability or binding mode to nonenal.
[0017] The skin damage suppression agent of the present invention contains the above-mentioned nonanal masking agent as an active ingredient. The skin damage suppression agent of the present invention and the nonanal masking agent (hereinafter, these may be collectively referred to as "the agent of the present invention") may contain any one of the above-mentioned active ingredients alone, or may contain two or more kinds in any combination and ratio.
[0018] Skin damage includes, but is not limited to, thinning of the skin of animals, including humans, and / or inhibition of skin cell proliferation. The present inventors have shown that adding nonenal to a skin model causes thinning and inhibition of skin cell proliferation. Inhibition of skin cell proliferation and / or thinning of the skin has adverse effects such as wrinkles, shrinkage, sagging, skin aging, reduced elasticity, reduced skin function, fatigue, and reduced resistance to external stimuli. Inhibition of skin damage caused by nonenal is expected to have effects such as prevention and improvement of wrinkles, shrinkage, sagging, skin aging, etc., as well as improvement of skin elasticity, skin function, resistance, etc.
[0019] It is believed that the skin damage inhibitor of the present invention inhibits damage such as skin thinning and / or damage due to cell proliferation inhibition, etc., through masking of nonenal by the nonenal masking agent. Although the mechanism of action has not been elucidated, it is believed that the mechanism of action may be related to the fact that the nonenal masking agent binds to nonenal, thereby reducing or preventing the binding of nonenal to CNG channels, or reducing or preventing the electrical signal generated by the binding of nonenal to olfactory receptors.
[0020] In one embodiment, the agent of the present invention contains one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde as an active ingredient or consists of such a compound.
[0021] Benzaldehyde (also known as benzenecarbaldehyde) is an aromatic aldehyde with the following structure: Benzaldehyde may be artificially synthesized, a commercially available product may be used, or it may be used in the form of an essential oil or extract, since it is present in natural products such as almond, apricot, and peach seeds. [ka]
[0022] Dihydromyrcenol (also known as 2,6-dimethyl-7-octen-2-ol) is an organic compound with the following structure. It can be artificially synthesized, a commercially available product, or used in the form of a natural essential oil or extract. [ka]
[0023] Linalool is a monoterpene alcohol having the following structure. It may be in any form of R-, S- or racemic form. Linalool may be artificially synthesized or commercially available, and may be used in the form of essential oils or extracts of rosewood, neroli, lavender, bergamot, clary sage, coriander, etc. [ka]
[0024] Phenylethyl alcohol (also known as 2-phenylethanol, 2-phenylethyl alcohol, and β-phenylethyl alcohol) is an aromatic alcohol with the following structure: Phenylethyl alcohol may be artificially synthesized or commercially available, and may be used in the form of essential oils or extracts from roses and other plants. [ka]
[0025] Benzyl acetate is an ester having the following structure: Benzyl acetate may be artificially synthesized or a commercially available product may be used, and since it is present in jasmine, ylang-ylang, gardenia, and many other flowers, it may be used in the form of an essential oil or extract thereof. [ka]
[0026] Anisaldehyde (also known as p-anisaldehyde or 4-methoxybenzaldehyde) is an organic compound with the following structure. Anisaldehyde can be artificially synthesized or commercially available, and can also be used in the form of an essential oil or extract, as it is found in anise. [ka]
[0027] When using essential oils, the flowers, leaves, fruit skins, bark, roots, seeds, etc. of the above-mentioned plants can be dried and subjected to any method such as steam distillation, squeezing, solvent extraction, etc. can be used. When using extracts, the extraction method is not particularly limited, but extracts obtained by extraction methods using lower alcohols such as ethanol, organic solvents such as hexane, or mixed solvents thereof such as hexane / ethanol can be used. By the essential oil extraction operation, essential oil extracts containing active ingredients can be obtained, which may be used as they are, or may be used after conventional purification treatments such as sterilization, washing, filtration, decolorization, and deodorization. In addition, they may be used after concentration or dilution as necessary.
[0028] The agent of the present invention may be a composition in which the above-mentioned active ingredient is combined with one or more other ingredients, such as an excipient, a carrier, and / or a diluent. The composition may have any composition or form, and may be appropriately selected depending on the active ingredient, the intended use, and other conditions. The composition may be produced by a conventional method in a formulation in which the active ingredient is appropriately combined with an excipient, a carrier, and / or a diluent, etc., and other ingredients depending on the dosage form.
[0029] For example, the agent of the present invention can be incorporated into compositions such as cosmetics, quasi-drugs, medicines, and functional foods for the purpose of preventing and improving skin thinning, preventing and improving wrinkles, shrinkage, sagging, skin aging, and the like, and improving skin elasticity, skin function, and resistance. When incorporated into cosmetics, it can be incorporated into any cosmetics that are applied to the skin, such as sunscreens, lotions, beauty essences, beauty creams, and aftercare lotions. It is preferable to incorporate it into skin external preparations that can be applied directly to the skin. The agent of the present invention can be appropriately incorporated with optional ingredients used in compositions such as cosmetics and medicines, as necessary, within a range that does not impair its effects. Examples of the optional ingredients include oils, surfactants, powders, colorants, water, alcohols, thickeners, chelating agents, silicones, antioxidants, ultraviolet absorbers, moisturizers, fragrances, various medicinal ingredients, preservatives, pH adjusters, and neutralizers. For example, other medicinal ingredients that promote nonanal masking action and skin damage inhibition may be included.
[0030] When the present invention is applied to skin external preparations such as cosmetics, medicines, and quasi-drugs, the nonenal masking agent in the agent or composition of the present invention is not limited as long as it does not impair the nonenal masking effect of the present invention, and can be appropriately determined depending on the type, purpose, form, method of use, etc. For example, a nonenal masking agent such as one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde can be blended in any ratio, such as 0.0001 to 0.001 wt%, 0.001 to 0.005 wt%, 0.005 to 0.01 wt%, 0.01 to 0.02 wt%, 0.02 to 0.05 wt%, 0.05 to 0.1 wt%, 0.1 to 1.0 wt%, 1.0 to 10 wt%, 10 to 50 wt%, or 50 to 100 wt%, in the total amount of the cosmetic.
[0031] However, the forms that the agent or composition of the present invention can take are not limited to the above-mentioned dosage forms or shapes.
[0032] The present invention also provides a method for suppressing skin damage caused by nonenal by administering the agent or composition of the present invention. The method of the present invention is a method for cosmetic purposes and may not be a treatment performed by a doctor or medical professional.
[0033] The subject to which the agent or composition of the present invention is administered may be a subject in which skin damage caused by nonenal is objectively or subjectively recognized, or a subject wishing to prevent skin damage caused by nonenal. For example, the subject may be a subject who is judged to have a high amount of nonenal, yellowing of the skin, thinning, decreased cell proliferation, or has body odor, or a subject who is concerned about body odor or skin damage caused by nonenal, such as skin thinning, wrinkles, shrinkage, sagging, and decreased skin elasticity.
[0034] The present invention also provides a method for screening skin damage inhibitors using the nonenal masking activity as an index. The screening method of the present invention may include a step of measuring the nonenal masking activity of a candidate drug, and a step of selecting a skin damage inhibitor based on the nonenal masking activity of the candidate drug. The method of the present invention makes it possible to screen whether a candidate drug has an anti-photoaging effect, and thus makes it possible to develop products and propose new skin care methods. EXAMPLES
[0035] The present invention will now be described in more detail with reference to examples, although the present invention is not limited thereto.
[0036] Experiment 1: Evaluation of malodorous substances Experiment 1-1: Preparation of odorous substances The following known substances having a malodor were used:
[0037] [Table 1]
[0038] Experiment 1-2: Effects of malodorous substances on the skin In order to confirm the effect on the skin of the malodorous substance prepared in Experiment 1-1, the following experiment was carried out. Human epidermal cells (4,000 cells) were cultured in Humedia-KG2 (Kurabo) medium for 3 days at 37°C, after which the substance from Experiment 1 was added to the medium at 50 μM. As a control, the same amount of the solvent ethanol was added. After addition, the cells were cultured at 37°C for 24 hours, and the number of cells after addition was counted. The percentage of cells when the substance was added relative to the number of control cells was calculated using the following formula to determine the survival rate.
number
[0039] The results are shown in Figure 1. As shown in Figure 1, the use of nonenal significantly reduced cell viability compared to other malodorous substances, indicating that it is toxic to skin cells.
[0040] Experiment 2: Evaluation of cytotoxicity due to different concentrations of nonenal Next, the concentration dependence of cytotoxicity by nonenal was investigated by determining cell viability in the same manner as in Experiment 1-2, except that nonenal, which was found to be toxic in Experiment 1, was used at various concentrations (0 μM, 5 μM, 10 μM, 25 μM, 50 μM). The results are shown in Figure 2. As shown in Figure 2, the cell viability decreased significantly with increasing concentration of nonenal, indicating that the cytotoxicity of nonenal is concentration-dependent.
[0041] Experiment 3: Evaluation of substances with nonenal-masking activity Experiment 3-1: Preparation of the substance to be evaluated The following substances, which may or may not have a nonenal-masking effect, were used as the substances to be evaluated.
[0042] [Table 2]
[0043] Experiment 3-2: Cytotoxicity of the substance to be evaluated The cytotoxicity of the target substance was examined by determining the cell viability in the same manner as in Experiment 1-2, except that the target substance was used at various concentrations (5 μM, 50 μM, 500 μM) instead of the malodorous substance. The results are shown in Figure 3. From Figure 3, it was confirmed that the above-mentioned evaluation substances except for β-damascone did not have cytotoxicity.
[0044] Experiment 3-3: Inhibitory effect of the evaluation substance nonenal on skin damage The effect of the evaluation target substance in suppressing skin damage caused by nonenal was investigated by determining cell viability in the same manner as in Experiment 1-2, except that 5 μM of the evaluation target substance and various concentrations (5 μM, 50 μM, 500 μM) of nonenal were used. The results are shown in Figure 4. As can be seen from Figure 4, the addition of only nonenal reduced cell viability in a concentration-dependent manner, but the addition of a substance with a nonenal-masking effect inhibited the decrease in cell viability. On the other hand, the addition of a substance without a nonenal-masking effect did not inhibit the decrease in cell viability.
[0045] Experiment 4: Inhibitory effect of nonenal on skin damage using a 3D skin model Experiment 4-1: Creation of a 3D skin model Human epidermal cells (2.2 × 10 ) diluted in CnT Prime medium (CELLnTEC) were placed on cell culture inserts (φ12 mm, average pore size of porous membrane: 0.4 μm) coated with CellStart (Invitrogen Life Technologies) solution diluted 50-fold in DPBS. 5Cells were seeded with 1000μl of CnT Prime medium (CELLnTEC) and 1ml of CnT Prime medium (CELLnTEC) was added under the insert and cultured at 37℃ for 3 days. After that, the medium on the insert was replaced with 500μl of CnT-PR-3D medium (CELLnTEC) supplemented with vitamin C (50μg / ml) and the medium under the insert was replaced with 1ml, and cultured at 37℃ for 1 day. After 1 day, the medium on the insert was sucked out and the medium under the insert was replaced with 500μl of CnT-PR-3D medium (CELLnTEC) supplemented with vitamin C (50μg / ml), and cultured at 37℃ for 1 day. This procedure was repeated for 8 days to construct a 3D skin model.
[0046] Experiment 4-2: Evaluation of the effect of the evaluation substance, nonenal, on skin damage suppression based on skin thickness Three days before completion of the skin models prepared in Experiment 4-1, 50 μM nonenal alone, or 50 μM nonenal and 50 μM of each of the substances to be evaluated were added to the skin models prepared in Experiment 4-1. As a control, the same amount of the solvent, ethanol, was added and the models were cultured at 37°C for three days. The results are shown in Figures 5 and 6. As can be seen from these figures, the addition of nonenal caused skin thinning, but the addition of the evaluation target substance with nonenal masking activity inhibited skin thinning. On the other hand, the addition of a substance without nonenal masking activity did not inhibit such skin thinning. These results are consistent with the results of Experiments 2 to 3.
[0047] Experiment 4-3: Evaluation of the effect of the evaluation substance, nonenal, on skin damage inhibition by the number of proliferating cells Three days before the completion of the skin model prepared in Experiment 4-1, 50 μM nonenal alone or 50 μM nonenal and 50 μM of each evaluation target substance were added, and the same amount of ethanol as a solvent was added to the control, and the skin model was cultured at 37 ° C for 2 days, and BrdU primary antibody (Abcam, Ab6326) was added to the medium at 50 μM and cultured for another day at 37 ° C. The skin model was then stained with BrdU secondary antibody (DAKO, # E0468) (1 / 5000 dilution), the number of BrdU positive cells was counted, and the number of BrdU positive cells per 1 mm length (cells / mm) was calculated by dividing by the length of the skin model (total length of the skin model in the lateral direction).
[0048] The results are shown in Figures 7 and 8. As can be seen from these figures, the addition of nonenal reduced the number of proliferating cells in the skin and inhibited cell proliferation, but the addition of the evaluation target substance with nonenal masking activity inhibited the decrease in the number of proliferating cells. On the other hand, the addition of a substance without nonenal masking activity did not inhibit the decrease in the number of proliferating cells. These results are consistent with the results of Experiments 2 to 3.
[0049] These results suggest that nonenal has the effect of promoting skin damage, such as skin damage and / or skin thinning due to inhibition of skin cell proliferation, but that such skin damage can be suppressed by using nonenal masking agents such as benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde. These substances are expected to suppress skin damage and, in turn, prevent and improve wrinkles, sagging, sagging, and skin aging, as well as improve skin elasticity, skin function, and resistance.
Claims
1. an agent for suppressing skin damage caused by nonenal, including a nonenal masking agent; Here, the nonenal masking agent comprises one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde.
2. The method of claim 1 , wherein the skin damage is skin thinning.
3. A composition for suppressing skin damage caused by nonenal, comprising the agent according to claim 1 or 2.
4. A cosmetic method for suppressing skin damage caused by nonenal by applying a cosmetic product containing a nonenal masking agent to the skin. wherein the nonenal masking agent comprises one or more compounds selected from the group consisting of benzaldehyde, dihydromyrcenol, linalool, phenylethyl alcohol, benzyl acetate, and anisaldehyde; The cosmetic method is a method for cosmetic purposes and is not a treatment by a doctor or a medical professional.
5. The cosmetic method according to claim 4, wherein the skin damage is skin thinning.
Citation Information
Patent Citations
Composition for suppressing body odor
JP1999286423A
Aged body odor-restraining perfume composition
JP1999286428A
Cosmetic suitable for sequential use
JP2010043050A
Oxytocin production promoter
JP2011098898A
Evaluation model for dermal yellowing
JP2012032287A
